Patients with T2D who received GLP-1RAs or SGLT2 inhibitors were not associated with an increased risk for ARDs compared with DPP4 inhibitors.

The effect was seen across a wide variety of addictive and habit-forming substances, including cocaine, opioids, alcohol, ...

Sustained GLP-1 receptor agonist therapy is linked to greater improvements in A1c levels than DPP-4 inhibitor therapy in patients with type 2 diabetes, a Danish real-world analysis shows.

Here are five key takeaways for regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity. HealthDay News — From 2010 to 2023, there was an increase ...

In 524,817 adults with T2D, GLP-1 RA use was associated with lower incident alcohol, cocaine, cannabis, opioid, and nicotine ...

Popular drug class quiets "drug noise," says researcher ...

New research suggests the weight-loss medications could be powerful tools in tackling substance use disorders.

Please provide your email address to receive an email when new articles are posted on . No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs ...

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors demonstrated a nearly 50% lower risk for systemic autoimmune rheumatic disease vs. those who received dipeptidyl ...

GLP-1 receptor agonists used to treat type 2 diabetes and obesity could help reduce risk of addiction to substances like ...

Evidence continues to mount suggesting that GLP-1 drugs like Ozempic and Wegovy may help people cut back on cigarettes, ...